|
Daehan Nupharm Reports Cumulative Sales of KRW 153.6 Billion in Q3 2023
2023.11.14
|
|---|
|
Daehan Nupharm announced that its cumulative sales for the third quarter of 2023 reached KRW 153.6 billion, representing a 3.9% increase year-on-year. Cumulative operating profit came to KRW 18.1 billion, with an operating profit margin of 11.8%. The company is steadily progressing toward its annual sales target of KRW 200 billion and plans to further expand R&D investment to strengthen future growth drivers. Daehan Nupharm intends to focus on incremental drug development for prescription pharmaceuticals, while also enhancing dosing convenience through the development of new formulations for diabetes and obesity treatments. Strong growth in injectable products, one of the company’s core business strengths, continues to drive sales. In particular, wellness injections such as Vitamin C Injection and Luthione Injection are posting sustained growth. Sales of Liporase Injection, which contains hyaluronidase, are expected to exceed KRW 9 billion this year.
The company’s health functional food segment is also showing steady growth. Daehan Nupharm plans to launch a differentiated collagen product in December, further diversifying its portfolio. |


Home